Innate Pharma : Parfaitement financé pour atteindre ses catalyseurs de court terme
>Visibilité financière jusqu’à fin 2025 - Innate Pharma a publié ce matin son chiffre d’affaires et sa trésorerie au titre des 9 premiers mois de l’année. Le CA ressort à 10.2 M€ (vs 36.5 M€ en 2023) provenant principalement de la reconnaissance des paiements reçus dans le cadre de ses partenariats avec AstraZeneca et Sanofi.La trésorerie à fin septembre s’établit à 96.4 M€ ce qui devrait lui permettre de financer ses activités jusqu’à fin 2025. Soulignons que la...Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.